US 11,883,493 B2
Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
W. Jason Cummings, Bellevue, WA (US); Gregory A. Demopulos, Mercer Island, WA (US); Thomas Dudler, Bellevue, WA (US); Larry W. Tjoelker, Kirkland, WA (US); Christi L. Wood, Snohomish, WA (US); and Munehisa Yabuki, Seattle, WA (US)
Assigned to OMEROS CORPORATION, Seattle, WA (US)
Filed by Omeros Corporation, Seattle, WA (US)
Filed on Apr. 27, 2021, as Appl. No. 17/241,628.
Application 17/241,628 is a division of application No. 16/909,578, filed on Jun. 23, 2020, granted, now 11,027,015.
Application 16/909,578 is a division of application No. 16/837,600, filed on Apr. 1, 2020, granted, now 10,745,274, issued on Aug. 18, 2020.
Application 16/837,600 is a division of application No. 15/665,030, filed on Jul. 31, 2017, granted, now 10,639,369, issued on May 5, 2020.
Claims priority of provisional application 62/478,336, filed on Mar. 29, 2017.
Claims priority of provisional application 62/419,420, filed on Nov. 8, 2016.
Claims priority of provisional application 62/369,674, filed on Aug. 1, 2016.
Prior Publication US 2021/0275667 A1, Sep. 9, 2021
Int. Cl. A61K 39/395 (2006.01); C07K 16/40 (2006.01); C01F 17/206 (2020.01); B82Y 25/00 (2011.01); C09K 11/77 (2006.01); H01F 1/00 (2006.01); C12N 9/64 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/3955 (2013.01) [B82Y 25/00 (2013.01); C01F 17/206 (2020.01); C07K 16/40 (2013.01); C09K 11/77 (2013.01); C09K 11/7728 (2013.01); C12N 9/6424 (2013.01); C12Y 304/21104 (2013.01); H01F 1/0054 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C01P 2002/54 (2013.01); C01P 2002/84 (2013.01); C01P 2004/64 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01)] 17 Claims
 
1. An isolated antibody, or antigen-binding fragment thereof, that binds to MASP-3 comprising a heavy chain variable region comprising an HC-CDR1, an HC-CDR2, and an HC-CDR3 and a light chain variable region comprising an LC-CDR1, an LC-CDR2, and an LC-CDR3, wherein:
i) the HC-CDR1 comprises SEQ ID NO:56, the HC-CDR2 comprises SEQ ID NO:58, the HC-CDR3 comprises SEQ ID NO:60 and wherein the LC-CDR1 comprises SEQ ID NO:142, SEQ ID NO:257, SEQ ID NO:258 or SEQ ID NO:259; wherein the LC-CDR2 comprises SEQ ID NO:144 and wherein the LC-CDR3 comprises SEQ ID NO:146; or
ii) the HC-CDR1 comprises SEQ ID NO:62, the HC-CDR2 comprises SEQ ID NO:63, SEQ ID NO:67 or SEQ ID NO:69, the HC-CDR3 comprises SEQ ID NO:65 and wherein the LC-CDR1 comprises SEQ ID NO:149, the LC-CDR2 comprises SEQ ID NO:144 and the LC-CDR3 comprises SEQ ID NO:146.